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Abstract
Solid tumors often grow in a micro-environment characterized by < 2% O2 tension. This condition, together with
the aberrant activation of specific oncogenic patwhays, increases the amount and activity of the hypoxia-inducible
factor-1α (HIF-1α), a transcription factor that controls up to 200 genes involved in neoangiogenesis, metabolic
rewiring, invasion and drug resistance. Hypoxia also induces endoplasmic reticulum (ER) stress, a condition that
triggers cell death, if cells are irreversibly damaged, or cell survival, if the stress is mild.
Hypoxia and chronic ER stress both induce chemoresistance. In this review we discuss the multiple and
interconnected circuitries that link hypoxic environment, chronic ER stress and chemoresistance. We suggest that
hypoxia and ER stress train and select the cells more adapted to survive in unfavorable conditions, by activating
pleiotropic mechanisms including apoptosis inhibition, metabolic rewiring, anti-oxidant defences, drugs efflux. This
adaptative process unequivocally expands clones that acquire resistance to chemotherapy.
We believe that pharmacological inhibitors of HIF-1α and modulators of ER stress, although characterized by low
specificty and anti-cancer efficacy when used as single agents, may be repurposed as chemosensitizers against
hypoxic and chemorefractory tumors in the next future.
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Background: the impact of hypoxia on cancer and
its microenvironment
Cancer growth is supported by the continuous interaction
between transformed and non-transformed cells, including
cancer-associated fibroblasts, endothelial cells and immune-
infiltrating cells that constitute the so-called tumor
microenvironment (TME).
Within TME, cancer cells are subjected to multiple
stresses caused by shortage of oxygen (O2) and nutrients,
chronic inflammation, damages induced by immune cells
or exogenous factors, such as chemotherapy and radio-
therapy. O2 shortage is the most common condition that
tumors must face [1]. The highest O2 concentration
(13.2%) is measured in arterial blood and is considered
as normoxia [2]. Under physiological conditions, the O2
concentration in human tissues varies between 1 and
11%. Most solid tumors grow under hypoxic conditions,
i.e. below 2% O2 [3, 4].
When facing hypoxic conditions, cancer cells can
undergo two processes: slowing their progression and
ending-up in necrosis/apoptosis, or adapting to the
unfavorable conditions. This adaptation expands more
aggressive clones that become predominant in the tumor
heterogeneous population [5]. This process is mainly
orchestrated by hypoxia-inducible factors (HIFs), i.e. specific
hypoxia sensors that support cell survival by inducing
compensatory angiogenesis, extracellular matrix (ECM) re-
modelling, metabolic shift and immune-suppression [6–10].
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HIF proteins are dimers consisting of an unstable, O2-sensi-
tive α subunit and a costitutively expressed, O2-insensitive β
subunit. Three HIFɑ proteins - HIF-1ɑ, HIF-2ɑ and HIF-3ɑ,
each with multiple splicing variants – and one HIFβ protein
were identified in higher organisms [11]. Although HIF-1ɑ is
ubiquitary and HIF-2ɑ prevails in heart and liver, both of
them are expressed in many cancer types and have overlap-
ping functions. Little is known on HIF-3ɑ, whose study is
complicated by the multiple variants of this protein present
in humans [12].
Under normoxia, the labile ɑ subunits are hydroxylated
by the prolyl hydroxylase dioxygenase (PHD) enzymes [13],
which generate a binding site for the von Hippel Lindau
tumor suppressor protein (pVHL). Following the pVHL
binding, HIFɑ is poly-ubiquitinated and then degraded by
the proteasome [14, 15]. PHD is an O2-dependent enzyme:
under hypoxic conditions, HIFɑ is not primed for ubiquiti-
nation, but it accumulates and binds to its β subunit, and is
free to translocate into the nucleus [16, 17]. Besides hyp-
oxia, HIF-1ɑ stabilization may be promoted by oncogenic
activation of pro-survival pathways such as Ras/PI3K/Akt/
mTOR [18], mutations in key oncosuppressor genes such
as TP53 [19] or BRCA1/PTEN axis [20], metabolites
paracrinely released in the TME such as glutamate
[21]. Similarly, the intracellular accumulation of reactive
oxygene species (ROS) inactivates PHD, increasing HIF-1ɑ
within tumors [11].
Specific miRNAs stabilize HIF-1ɑ [22] and are involved
in the hypoxia-mediated modulation of angiogenesis,
apoptosis, proliferation, metastasis and chemoresistance
[23]. For instance, the increase in HIF-1α is associated to
the up-regulation of miR-155, miR-10b, miR-372, miR-
373, miR-210 and miR-519c, and to the down-regulation
of miR-17-92, miR-20b, miR-200b and miR-199 [24].
HIF proteins induce up to 200 genes that promote
adaptation to hypoxia [6, 11], involved in proliferation,
glucose metabolism and angiogenesis in many different
cancer types [25–27]. Among them, there are glucose
transporter 1 (GLUT1), which increases the glucose
uptake fuelling the anaerobic glycolysis, and vascular
endothelial growth factor (VEGF), a well-known angio-
genic factor [28]. HIF-1α is a strong inducer of other
glycolytic enzymes that contribute to an increased rate of
anaerobic glycolysis, coupled with a lower rate of tricarb-
oxylic acid (TCA) cycle. This phenotype is typical of
several solid cancers addicted to glucose as the main fuel
source [29]. In addition, HIF-1ɑ down-regulates oxidative
phosphorylation (OXPHOS) by inducing the Hes-related
family BHLH transcription factor with YRPW motif
(HEY) repressor [30], decreases the expression of carnitine
palmitoyl transferase 1A (CPT1A), the limiting-enzyme of
fatty acid β-oxidation (FAO) [31] and inhibits the electron
transport chain (ETC) [32]. As a result, both anaplerotic
pathways of TCA cycle and ETC are limited. The main
benefit derived from the inhibition of mitochondrial me-
tabolism is the decreased level of ROS and the prevention
of cytotoxic oxidative stress [33].
Both HIF-1ɑ and HIF-2ɑ promote a more invasive
phenotype [33], by activating the epithelial-mesenchymal
transition (EMT) program [34–36] or cooperating with
other strong pro-invasive factors such as Met receptor
and soluble hepatocyte growth factor (HGF) [37], or
VEGF receptor (VEGFR)/VEGF [38]. Notably, in triple
negative breast cancer (TNBC) HIF-1ɑ stimulates the
relase of the typical pro-inflammatory cytokine IL-1β
that induces a metastatic attitude in both tumor cells
and cancer associated fibroblasts (CAFs), creating a
TME that strongly favors metastatization [39]. In
addition, HIF-1ɑ also promotes a tumor-tolerant environ-
ment, reducing the infiltration of CD4+ and CD8+ T-
lymphocytes and tumor-associated macrophages (TAMs)
[40], increasing the differentiation of T-lymphocytes into
T-helper 17 (TH17) cells [41] and modulating TAM
polarization [42]. Overall, the hypoxia-driven reshaping of
immune-environment is associated to increased tumor
progression, particularly in the early stages [43].
Given the pleiotropic functions regulated, HIF-1ɑ ex-
pression has been used as a stratification factor. Specific
signatures of HIF-1ɑ-target genes have a negative prog-
nostic significance in hepatocellular carcinoma (HCC)
[44]. Similarly, a meta-analysis focused on the prognostic
role of HIF-2ɑ demonstrated that a higher expression of
this transcription factor is associated with a worst overall
survival, metastasis-free and progression-free survival in
melanoma, breast and lung cancer [45].
Hypoxia and nutrients shortage are two classical condi-
tions inducing endoplasmic reticulum (ER) stress, a
perturbation of the ER homeostasis that determines the
accumulation of unfolded or misfolded proteins within ER
lumen. As hypoxia does, also ER stress may evolve into
two opposite situations: the activation of pro-apoptotic
program, with consequent cell death in case of acute ER
stress, or the activation of pro-survival responses, in case
of chronic and mild ER stress [46]. In a strict parallelism
with hypoxia, also ER stress determines the selection of
tumor populations with a multistress-resistant phenotype,
i.e. able to survive in the presence of unfavorable and
changing conditions, such as O2 and nutrients shortage,
or exposure to chemotherapeutic drugs [47]. Solid tumors
experiment continuous changes in O2 and nutrients
supply. Indeed, if the hypoxia-induced neo-angiogenesis
provides O2 and nutrients, the neo-vessels formed easily
collapse under the pressure of the growing tumor mass.
This situation implies that repeated cycles of hypoxia and
re-oxygenation occur within the tumor, and that nor-
moxic and hypoxic areas coexist within the tumor bulk.
The poorly organized vasculature also determines an
irregular delivery of chemotherapeutic drugs. Tumors are
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heterogeneous masses composed by hypoxic niches,
characterized by severe shortage of O2 and nutrients, and
stronger ER stressing conditions, and well-oxygenated
areas, less subjected to ER stress [48, 49]. In this review,
we will discuss how the adaptation to hypoxia and to the
hypoxia-induced ER stress contribute to the expansion of
aggressive tumor clones and to the acquisition of
chemoresistance, by triggering pro-survival/anti-apoptotic
responses. A better knowledge of the cross-talks betweeen
hypoxia and ER stress may open new therapeutic oppor-
tunities effective against tumors refractory to classical
chemotherapy, by targeting HIF activation and modulat-
ing the response to ER stress.
The variable response to ER stress in cancer cells
In eukaryotic cells, protein folding and maturation are han-
dled by ER, where nascent polypeptide chains synthesized
by ribosomes are folded and undergo post-translational
modifications, such as disulfide bonds formation and glyco-
sylation. Synthesized proteins must pass the ER-associated
protein degradation/ER-quality control (ERAD/ERQC)
system, constituted by ER-associated protein complexes
that deliver the properly folded proteins to their final
destination, the unfolded/misfolded proteins to ubiquitina-
tion and degradation via proteasomes or autophagosomes/
lysosomes [50, 51]. ERAD/ERQC proteins are often over-
expressed in cancers [52], as part of an adaptive response
that help cancer cells to survive in unfavorable environ-
ments. Upon glucose deprivation, oxidative stress, aging or
hypoxia, ERAD/ERQC system can be overwhelmed. Un-
folded proteins accumulate within the ER lumen, triggering
the so-called unfolded protein response (UPR) that results
in cell death or ER stress compensation and consequent
survival [46, 53, 54].
When unfolded proteins accumulate, ER-resident
chaperones such as glucose-regulated protein 78
(GRP78) increases the folding capacity or proceeds to
the clearance of unfolded proteins via ERAD machinery.
In parallel, protein translation is reduced, to limit the
burden of unfolded proteins accumulated within the ER
lumen [55]. If both options fail, cells initiate apoptosis
[54]. Inositol-requiring enzyme-1α (IRE1α), activating
transcription factor-6 (ATF6) and protein kinase R-like
endoplasmic reticulum kinase (PERK) are ER transmem-
brane proteins that act as ER-stress sensors and UPR
effectors [46, 53, 54], and are activated by GRP78 [56].
IRE1α activates X-box-binding protein 1 (XBP-1) that
up-regulates genes increasing proteins folding, ERAD
machinery and ER biogenesis [57, 58], or – if the ER
stress persists – up-regulates genes involved in apoptosis,
such as c-Jun N-terminal kinase 1 (JNK1) [56].
ATF6 controls the second arm of UPR. It increases the
transcription of chaperones and ERAD pathway members,
as well as GRP78, generating a feed-forward loop which
buffers ER stress [55].
The third sensor of UPR is PERK that - by phosphorylating
on serine the eukariotic initiating factor 2α (eIF2α) - reduces
the mRNA translation rate, attenuating the accumulation of
misfolded proteins within ER [58, 59]. At the same time,
PERK increases the translation of the activating transcription
factor-4 (ATF4) that induces the transcription of chaperons,
anti-oxidant enzymes and enzymes involved in aminoacid
metabolism, favoring resistance to oxidative stress and drugs
[56]. ATF4 indeed may promote the transcription of CCAA
T/enhancer-binding protein homologous protein (CHOP)
that induces apoptosis in case of prolonged stress [46, 53,
54], but also protective autophagy [60].
Multiple cross-talks between the three arms of ER
stress exist. For instance, ATF6 also enhances IRE1α/
XBP-1 axis [61]. Together, they promote the degradation
of misfolded proteins during embryonic [62] and cancer
development [63]. Also PERK activates ATF6, by favor-
ing its synthesis and translocation from ER to Golgi [64].
Interestingly, as observed for HIF-1α [22, 24], miRNAs
act both as controllers of expression of UPR proteins
and modulators of the UPR response [65]. Only in one
case, miRNA expression changes in the same direction
under hypoxic conditions and ER stress: mir-17, which
is down-regulated by HIF-1α [24], is also reduced during
ER stress. Such decrease, favored by the activation of
IRE1α, promotes the switch from an adaptive UPR re-
sponse to a pro-apoptotic response [65]. This parallelism
suggests that specific miRNAs may contribute to the
effects that both HIF-1α and ER stress have on the cell
fate. These miRNAs may be part of the same molecular
circuitries, linking the hypoxic-induced ER stress to the
ER stress-induced cell death or survival. However, fur-
ther analyses are needed to unveil if other miRNAs have
the same modulation in case of hypoxia and ER stress,
or if hypoxia-dependent and UPR-dependent miRNAs
belong to two different and independent sets.
Overall, the redundancy of pathways facing ER stress,
the versatility of the response observed and the circuit-
ries influenced in the same way by hypoxia and ER stress
suggest that UPR is a crucial and finely regulated mech-
anism controlling the cell fate in response to pleiotropic
unfavorable conditions.
Hypoxia and ER stress: a double-liaison selecting
aggressive and resilient clones
Hypoxia is often a cause of ER stress, for at least two
reasons: first, specific processes physiologically occurring
within ER are altered in hypoxic conditions; second,
HIF-1α modulates the expression and activity of ER
stress sensors.
Many post-translational modifications are O2-dependent,
e.g. the oxidation and isomerization of cysteine thiol groups
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that form disulfide bonds, or the hydroxylation of collagen
on proline residues. In hypoxia, proteins are regularly
synthesized but their folding is impaired and induces ER
stress [66, 67]. Moreover, under hypoxic conditions, several
splicing variants of common proteins are produced [68]:
these variants may be sensed as abnormally folded proteins
by the ERAD/ERQC apparatus, triggering a UPR response.
Finally, the altered OXPHOS metabolism that is often
observed under hypoxia generates ROS, which oxidize
mitochondrial proteins and/or impact on their folding. This
triggers a mitochondrial UPR (mUPR) that is additive to
the ER-dependent UPR [69, 70].
On the other hand, HIF-1α controls the activity and
expression of UPR sensors. HIF-1α transcriptionally up-
regulates VEGF, which activates phospholipase C (PLC)
and inositol-3-phosphate (IP3)-dependent calcium release:
the oscillations in calcium levels trigger the activation of
UPR arms [71]. Although this mechanism was reported in
human endothelial cells, a similar cascade of events may
occur in hypoxic cancer cells, rich of VEGFR and autocri-
nely producing VEGF. In addition, hypoxia increases
GRP78 expression via extracellular signal-regulated kinase
(ERK) and protein kinase C (PKC) [72], thus activating the
primum movens of the three UPR arms. One mechanism
explaining the hypoxia-driven increase of GRP78 relies on
the cell migration-inducing and hyaluronan-binding pro-
tein (CEMIP), an ER-residing protein that is overex-
pressed in several solid cancers in response to hypoxia.
CEMIP transcriptionally up-regulates GRP78 and binds it
in the ER: the CEMIT/GRP78 complex increases glucose
uptake, prevents apoptosis and promotes cell migration
by raising the intracellular calcium and the activity of
PKCα [73], thus producing a better adaptation to
hypoxia.
The final results of the hypoxia-induced UPR are vari-
able, and depend on the degree and duration of hypoxia.
For instance, while HIF-1α and HIF-2α are activated
starting from < 3% O2, when the O2 tension is reduced
to 0.1% the mammalian target of rapamycin (mTOR) is
progressively inhibited and eIF2α is phosphorylated:
these two events reduce the global translation of
proteins [74].
The key role of PERK/eIF2α axis in pro-survival response
during hypoxia has been demonstrated by the fact that can-
cer cells with an intact PERK/eIF2α axis are more tolerant
to hypoxia and more tumorigenic [75]. These findings
suggest that PERK activity makes cancer cells more resilient
and aggressive. Notably, the activation of PERK is HIF-1α-
dependent and is stronger after normoxia-hypoxia cycles, a
condition often occurring within tumor bulks where the
vasculature is irregular [56]. The acquisition of hypoxia-
tolerance following PERK activation is mainly mediated by
the downstream effector ATF4. Indeed, tumors with defect-
ive PERK/eIF2α/ATF4 axis have apoptotic areas
overlapping with hypoxic areas [75], suggesting that a func-
tioning PERK/eIF2α/ATF4 is required to limit the hypoxia-
induced damages. Moreover PERK/eIF2α signalling
buffers the increasing ROS levels observed in cyclic
hypoxia, by increasing GSH and autophagy. These
events have improved the survival of glioblastoma cells
in response to the oxidative damages induced by oscil-
lating hypoxia or radiotherapy [76, 77]. In human cer-
vix cancer, the hypoxic induction of PERK/eIF2α/ATF4
signalling up-regulates the pro-metastatic protein
lysosomal-associated membrane protein 3 (LAMP3) [78],
linking hypoxic activation of PERK to another aggressive
behavior of cancer cells.
IRE1α/XBP-1 and ATF6 are also up-regulated during
hypoxia, although the biological meaning of their activa-
tion has been less studied. XBP-1 transcription and
splicing are higher in hypoxic tumors [79]. Like PERK,
also IRE1α modulates autophagy in response to hypoxia
[80], mounting a cytoprotective response. The use of
selective inhibitors of PERK and IRE1α, however, clari-
fied that the blocking of IRE1α and XBP-1 splicing did
not reduce cell proliferation during hypoxia, contrarily
to the inhibition of PERK [81]. These observations sug-
gest a predominant role of PERK/eIF2α axis over IRE1α/
XBP-1 axis in hypoxia tolerance and tumor growth.
If it is well documented that hypoxia induces ER
stress, it is also true that ER stress sensors increase HIF-
1α activity and hypoxia-related events. Indeed, UPR
signalling potentiates the response to hypoxia by phos-
phorylating and activating HIF-1α, and by stabilizing
VEGF protein via the up-regulation of multiple chaper-
ones [82]. Also ATF4 and IRE1α are transcriptional acti-
vators of VEGF in hypoxic cells, where they cooperate
with HIF-1α [83]. Such crosstalk between hypoxia and
UPR is not limited to specific genes, but it is part of a
more generalized response: in hypoxic TNBC, XBP-1
enhances the transcription of HIF-1α-target genes by
directly interacting with HIF-1α and recruiting the RNA
polymerase II on specific promoters. This XBP1-HIF-1α-
dependent signature is associated with tumor aggressive-
ness and poor prognosis [84].
Sometimes UPR- and hypoxia-driven responses do not
act in the same direction. Depending on the temporal
order of the events (i.e. UPR preceeding hypoxia or hyp-
oxia determining UPR), on the severity and duration of
hypoxia or ER stress, there can be contrasting responses.
For instance, upon strong ER stress, ATF4, activated by
p38 mitogen activated kinase (MAPK), down-regulates
apelin, an anti-apoptotic protein, which is up-regulated
by HIF-1α [85]: this is a typical case where the induction
of strong ER stress before the up-regulation of HIF-1α
induces cell death, preventing the typical anti-apoptotic
response mediated by HIF-1α. In a complementary situ-
ation, if hypoxia triggers a strong ER stress, ROS/p38
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MAPK axis, activated by HIF-1α, elicits a pro-apoptotic
response mediated by ATF4 [86], instead of a prolifera-
tive response as expected upon the usual activation of
MAPK proteins. Similarly, in breast cancer cells HIF-1α
induces immediately VEGF that favors neo-angiogenesis
and cell survival, but prolonged hypoxia activates the
IREα/XBP-1 axis that induces miR-153, a negative regu-
lator of HIF-1α [87]. Once the acute hypoxic insult is
over and a chronic hypoxic environment persists, cells
switch off the pro-survival programs driven by HIF-1α
and switch on pro-apoptotic programs. A two-phases re-
sponse is observed in prostate cancer (PC) and breast
cancer cells, as well as in osteosarcoma exposed to 1%
O2 tension: after an initial up-regulation of HIF-1α, the
protein is gradually reduced notwithstanding the persist-
ence of hypoxic conditions. Indeed, after 2–3 h of
hypoxia, a strong UPR is mounted, characterized by the
activation of PERK that destabilizes HIF-1α mRNA by
disrupting its interaction with the stabilizing protein YB-
1 [88]. In this case, the pro-survival programs induced
by HIF-1α are attenuated and the pro-apoptotic pro-
grams controlled by UPR determines cell death.
Beside the duration and extent of hypoxia or ER stress,
the presence of specific oncogenic pathways is another
factor that may direct hypoxia- and UPR-dependent pro-
grams towards antagonistic directions. For example, in
colon cancer the hyper-activated WNT/β-catenin axis
disrupts the interaction between XBP-1 and HIF-1α,
attenuating the transcriptional activity of HIF-1α and
decreasing the adaptation to hypoxia [89]. This response
is in contrast with what observed in TNBC, where – in
the absence of non-oncogenically active β-catenin -,
XBP-1 and HIF-1α cooperate in up-regulating a com-
mon set of target genes [84].
These prototypical examples suggest that HIF-1α- and
UPR-driven pathways can be linked by synergistic or
antagonistic cross-talks, depending on duration, degree
and timing of hypoxia and ER stress. Adaptation to
hypoxia and UPR are dynamic processes. Hence, static
measures cannot be conclusive because they do not
follow the evolution of hypoxic insults and the cellular
compensatory responses. Time-lapse approaches provide
significantly more information on the temporal and molecu-
lar hierarchy of HIF-1α- and UPR-dependent events, unveil-
ing the cause-effect relations existing in each situation.
Given the high heterogeneity of TME in terms of O2
and nutrients supply, cancer cells must continuously adapt
to conditions that change spatially and temporally. If the
process fails, pro-apoptotic pathways prevail and cells are
eliminated. If the process is successful, this continuous
adaptation promotes cell survival and tumor progression.
The first scenario sensitizes cells to the damages exerted
by radiotherapy and chemotherapy; the second scenario is
unequivocally associated to therapy-resistance (Fig. 1).
Hypoxia and altered UPR: two partners in crime
of chemoresistance
Hypoxia drives the acquisition of chemoresistance
In vitro, hypoxia has been reported to induce resistance
to several anti-cancer drugs, including Vinka alkaloids,
anthracyclines, cisplatin, etoposide, actinomycin-D, 5-
fluorouracil, gemcitabine, methotrexate, in different solid
cancers [90].
Both HIF-1α-dependent and indepedent mechanisms
are responsible for the chemoresistance related to hyp-
oxia. It is well documented that hypoxic tumors have a
poor vascularization that limits drug bioavailability [91].
In addition, the low O2 tension reduces the possibility of
inducing oxidative stress that is often a mechanism of
killing exerted by chemotherapeutic drugs [36], such as
cisplatin [92], doxorubicin, etoposide [93], gemcitabine
[94]. Moreover, by creating an unfavorable environment,
hypoxia selects aggressive and metastatic clones, as well
as clones rich of anti-apoptotic proteins such as IAP3
and Bcl-2: this selection is independent on HIF-1ɑ
activation [95], but it contributes to counteract the
apoptosis induced by anti-cancer agents.
Most frequently, the ample transcriptional program
induced by HIF-1α is the main responsible for the simul-
taneous resistance to drugs unrelated for structures and
mechanisms of action (Fig. 2). Among the main target of
HIF-1α there is mdr1 gene, which encodes for P-
glycoprotein/ATP binding cassette transporter B1 (Pgp/
ABCB1) [96]. This protein effluxes many chemotherapeu-
tic drugs, contributing to tumor multidrug resistance
(MDR) [97]. In vitro 3D-models mimic well the chemore-
sistance observed in the hypoxic core of solid tumors:
both hormone-dependent and TNBC 3D models display a
significant activation of HIF-1α, coupled with an increased
Pgp up-regulation and resistance to doxorubicin, com-
pared to parental 2D-cultured doxorubicin-sensitive cells
[98, 99]. The reversion of doxorubicin resistance and the
down-regulation of Pgp after HIF-1α inhibition with 3-
(5′-hydroxymethyl-2′-furyl)-1-benzimidazole or HIF-1α
shRNA, prove the molecular linkage between hypoxia and
HIF-1α-driven Pgp expression [98]. Notably, chemoresis-
tant tumors often have activated HIF-1α in normoxia, as a
result of the activation of Ras/ERK1/2 and RhoA/RhoA
kinase axes that phosphorylate and stabilize HIF-1α. This
kind of HIF-1α activity was detected in colon cancer,
malignant pleural mesothelioma, non-small cell lung can-
cer (NSCLC), TNBC and chronic lymphatic leukemia cells
[100–104]. This series of studies highlights that HIF-1α
alone is sufficient to induce a MDR phenotype by increas-
ing the expression of Pgp, independently of hypoxia. In
line with this observation, the oncogenic-driven activation
of HIF-1α is as strong as the hypoxic TME in determining
chemoresistance. Hence, we may hypothesize that HIF-
1α-dependent chemoresistance occurs both in hypoxic
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tumor areas and in well-oxygenated ones characterized by
a hypoxia-independent activation of HIF-1α. These two
scenarios are not antagonistic, but can co-exist, as in the
case of multiple myeloma (MM): growing in an hypoxic
niche in bone marrow, MM has a canonical activation of
HIF-1α that induces chemoresistance, but also the
concurrent activation of oncogenic pathways (e.g. Wnt,
Notch, Ras/MAPK-, PI3K, Akt/mTOR-, NF-kB-dependent
pathways) that prevent the apoptosis induced by chemo-
therapeutic drugs [90, 105].
Other MDR-related transporters are under the transcrip-
tional control of HIF-1α, such as MDR related protein 1/
ABC transporter C1 (MRP1/ABCC1) and lung resistance
protein (LRP) [106]. Breast cancer resistance protein/ABC
transporter G2 (BCRP/ABCG2) is up-regulated by both
HIF-1α [107], which is phosphorylated and stabilized by
ERK1/2 [108], and HIF-2α [109]. The simultaneous up-
regulation of different transporters enormously enlarges the
spectrum of drugs that lose efficacy in hypoxia or in tumors
with a constitutively active HIF-1α.
An additional tumor-intrinsic mechanism linking
hypoxia to chemoresistance involves the HIF-1α-driven
inhibition of TP53. Both HIF-1α and HIF-2α suppress
TP53-mediated apoptosis. This activity has been linked
to the resistance to 5-fluorouracil in TP53 wild-type
gastric cancers, but not in TP53-disrupted ones [110].
Notably, on the one hand HIF-1α destabilizes TP53, on
the other hand the binding of TP53 to HIF-1α impairs
the hypoxia-driven transcriptional program [111]: de-
pending on the mutational status of TP53 and/or on the
amount of HIF-1α, the interaction between these two
partners may produce pro-survival effects or cell death.
These two extremities oscillate from chemoresistance in
the first case to chemosensitivity in the second case.
HIF-1ɑ also prevents DNA double strand breaks, e.g.
by up-regulating topoisomerase 2A. This mechanism
confers resistance to etoposide in TNBC and PC [112].
This observation leads to the use of dual HIF/topoisom-
erase inhibitors (such as acriflavine) as potential antican-
cer and chemosensitizer agents [113]. At the same time,
Fig. 1 Hypoxia and ER stress select aggressive tumor clones. Hypoxia increases the stabilization of the hypoxia-inducible factor-1α (HIF-1α), by
preventing its degradation operated by prolyl hydroxylase dioxygenase (PHDs) enzymes. Together with chemotherapy and nutrient shortage,
hypoxia is also a strong inducer of ER stress. The increased burden of unfolded proteins is sensed by the glucose-regulated protein 78 (GRP78),
which is also a HIF-1α-target gene. The GRP78 downstream effectors – namely inositol-requiring enzyme-1α (IRE1α), activating transcription
factor-6 (ATF6) and protein kinase R-like endoplasmic reticulum kinase (PERK) – are activated. IRE1α induces the splicing (s) of X-box-binding
protein 1 (XBP-1) into its active form; PERK phosphorylates the eukariotic initiating factor 2α (eIF2α) that increases the translation of activating
transcription factor-4 (ATF4); ATF6 is cleaved by the Golgi site-1/site-2 proteases (S1P, S2P) into its nuclear (N) translocated form. XBP-1 s, ATF4
and ATF6N cooperate with HIF-1α in increasing the transcription of genes involved in neo-angiogenesis (vascular endothelial growth factor,
VEGF), invasion (matrix metalloproteases, MMP), metabolic rewiring (glucose transporter 1, GLUT1), pH homeostasis (carbonic anhydrases, CAs),
drug efflux (multidrug resistance 1, MDR1). These coordinated transcriptional programs promote the selection of tumor clones adapted to survive
in unfavorable conditions, characterized by chemoresistant and pro-metastatic phenotypes
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HIF-1ɑ increases the expression of DNA repair machin-
ery, such as DNA-PKs, Ku80 and Ku70 [114]: this mech-
anism, which contributes to the adaptation and survival
in conditions of chronic hypoxia [115], also protects
from DNA-damaging chemotherapeutic drugs.
The metabolic rewiring driven by hypoxia also plays a
role in chemoresistance [116]. The huge production of
lactate due to the increase in glycolysis determines a
strong acidification of the TME that limits the efficacy
of weak bases such as anthracyclines: indeed, these drugs
are easily protonated and sequestered within lysosomes
[117]. In the attempt of counteracting the strong acidifi-
cation, cancer cells up-regulate carbonic anhydrase (CA)
IX and XII, both under the transcriptional control of
HIF-1α [118, 119]. Also this event, however, is func-
tional to induce chemoresistance. Indeed, CAXII inter-
acts with Pgp and stimulates its activity, by creating a
slightly alkaline pH in the membrane domains where the
protein operates [119], and granting the maximal effi-
ciency of the pump [120].
By down-regulating OXPHOS [30] and inducing mito-
phagy [121, 122], HIF-1α favors chemoresistance by mul-
tiple and interconnected mechanisms. Chemotherapeutic
drugs as 5-fluorouracil and cisplatin increase ROS gener-
ation [110]. The lower levels of OXPHOS detected in
hypoxic cells or in cells with high levels of HIF-1α may
explain the lower generation of ROS and the reduced
oxidative damages induced by chemotherapy in these
conditions [123]. Moreover, the reductive catabolism of
glutamine – i.e. the cytosolic transformation of glutamine
into citrate – is a hallmark of hypoxic tumors [124]. This
pathway produces NADPH, provinding additional ROS-
buffering agents that limit the oxidative damages elicited by
chemotherapy. Of note, ROS are also necessary to stabilize
TP53 and trigger apoptosis [110]: therein, HIF-1α-positive
cells have a lower pro-apoptotic activity of TP53 in
response to chemotherapeutic drugs as cisplatin [125].
HIF-2α exerts a similar contribution by decreasing intracel-
lular ROS and limiting the stability of TP53 [110], thus
providing an additional loop that induces resistance to
Fig. 2 Hypoxia induces chemoresistance. Besides the stabilization of the hypoxia-inducible factor-1α (HIF-1α) due to the low activity of prolyl
hydroxylase dioxygenase (PHDs) enzymes, oncogenically activated axes downstream receptor tyrosine kinases, such as PI3K/Akt/mTOR and Ras/
Raf/MAPK axes, contribute to increase the amount of transcriptionally active HIF-1α. Among the target genes there are several ATP binding
cassette (ABC) transporters involved in chemotherapeutic drug efflux (e.g. ABC transporter B1/multidrug resistance 1, ABCB1/MDR1, encoding for
P-glycoprotein; ABC transporter C1/multidrug drug resistance related protein 1, ABCC1/MRP1; ABC transporter G2/breast cancer resistance protein,
ABCG2/BCRP; lung resistance protein, LRP), and genes involved in DNA repair, such as topoisomerase 2A (TOP2A), DNA-PK, Ku-70 and Ku-80,
preventing the DNA damage elicited by chemotherapy. HIF-1α also inhibits TP53-induced apoptosis in repsonse to chemotherapy, by
destabilizing TP53. In addition, hypoxia is associated with other events determining chemoresistance, such as the increase in mitophagy that
spares ATP, the reduction of oxidative phosphorylation (OXPHOS) and reactive oxygen species (ROS) that reduce oxidative damage, the increase
of the anti-apoptotic proteins Bcl-2 and IAP3. The sum of these hypoxia-driven responses, either HIF-1α-dependent or independent, make
hypoxic cells highly chemoresistant
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oxidative stress and chemotherapy. Mitophagy allows can-
cer cells to recover ATP, redox metabolites and building
blocks, that can be used to re-synthesize biomolecules dam-
aged by chemotherapeutic drugs, providing an additional
mechanism by which the altered mitochondrial metabolism
induced by HIF-1α determines chemoresistance. For in-
stance, HIF-1α triggers a protective mitophagic response
and at the same time confers resistance to 5-fluorouracil
[126], gemcitabine [94] and cisplatin in ovarian cancer
[123]. Indeed the increased rate of mitophagy [121, 122],
favored by the up-regulation of the mitophagic Bcl-2/
adenovirus E1B 19-kDa interacting protein 3 (BNIP3) by
HIF-1α [127], compensates the lower ATP produced by
OXPHOS. ATP is a necessary substrate for ABC trans-
porters and favors the efflux of multiple chemotherapeutic
drugs.
HIF-1α is also a strong inducer of glutaminolysis [128]
that can be reduced into citrate and generate NADPH
[124], or can fuel the TCA cycle. This anaplerotic
pathway, together with the reshaping of mitochondrial
cristae that maximizes the ATP synthesis [129] and the
increased mitobiogenesis caused by the up-regulation of
the peroxisome proliferator-activated receptor gamma
coactivator-1α (PGC-1α) observed in hypoxic and acidic
tumors [130], compensate the attenuated TCA cycle and
OXPHOS induced by hypoxia.
This metabolic phenotype allows hypoxic cancer cells
to rely mainly on a glycolytic metabolism, but to switch
toward a mitochondrial metabolism when glucose is low.
This plasticity ensures a high adaptability to the meta-
bolic changing conditions of the TME, granting the
possibility of supplying energy and building blocks by
rewiring the metabolism. As a consequence, hypoxic
cells are less susceptible to the oxidative and energetic
damages produced by chemotherapy.
Other chemoresistance inducers that can be up-
regulated by HIF-1α are Pim kinases members [131]
which phosphorylate and activate Pgp [132]. Also the
NF-kB and Akt/mTOR axes, which are increased in
hypoxia, may activate Pim kinases [121], amplifying
chemoresistance. Collectively, Pim kinases have been
implicated in resistance to cisplatin, doxorubicin and
gemcitabine in pancreatic adenocarcinoma (PDAC) cells,
and to docetaxel in PC cells [132, 133]. Interestingly, also
specific miRNAs associated with HIF-1α up-regulation are
involved in chemoresistance. For instance, the HIF-1α/
mir-210 axis determines resistance to temozolomide in
glioblastoma by increasing the cell proliferation and the
acquisition of a stemness phenotype [134]. In keeping with
these results, mir-210 is considered a biomarker predictive
of chemoresistance in patients with metastatic breast can-
cer [135]. Mir-519c up-regulates ABCG2 [136], a gene tar-
get of HIF-1α [107], providing an explanation for the
ABCG2-mediated chemoresistance detected in tumors
with high expression of HIF-1α. mir-10b confers resist-
ance to 5-fluorouracil in colorectal cancer, where it in-
hibits the pro-apoptotic BH3-only Bcl-2 family member
BIM (BCL2L11) and is considered a negative prognostic
factor in chemotherapy-treated patients [137]. Similarly,
miR-155, which determines chemoresistance in solid and
hematological tumors [138], is considered a negative
prognostic marker in breast cancers [139]. The correlation
between high HIF-1α, high levels of miRNAs dependent
on HIF-1α and chemoresistance, however, is not univocal.
Indeed, mir-372 is a predictor of chemosensitivity in colo-
rectal cancer [140] and mir-373 chemosensitizes gastric
cancer cells [141], although they are both increased by
HIF-1α [24]. Thse data suggest that many other factors
can intervene to determine if a specific miRNA induced
by hypoxia causes chemoresistance or not.
Senescence is another process often associated with
drug resistance [142] and sustained by HIF-1α, both in
normoxia [110] and hypoxia [143]. Hypoxic cells are
often quiescent or slowly cycling [91, 144]. These types
of cells are the most difficult to eradicate and the most
resistant to drugs interfering with cell cycle, such as
pemetrexed and raltitrexed [145]. By contrast, the sensitivity
towards drugs acting in a cell cycle-independent manner,
such as proteasome inhibitors, is preserved [145].
Finally, HIF-1α increases resistance to chemotherapy
by promoting EMT [36], which induces cell proliferation
and migration, as demontstrated by the down-regulation
of E-cadherin and the up-regulation of vimentin in hyp-
oxic PC cells. Propofol, recently identified as a HIF-1α
inhibitor, not only reduces EMT but also sensitizes cells
to docetaxel [146]. This mechanism is not drug- or
tumor-type specific, because it is elicited also by the nat-
ural product tanshinone IIA, another HIF-1α inhibitor
that impairs EMT and alleviates the hypoxia-induced re-
sistance to doxorubicin in breast cancer cells [147].
In general, hypoxic tumors display multiple and redundant
mechanisms of resistance to chemotherapy. Some molecular
circuitries involved in chemoresistance are part of the
adaptation strategies to hypoxia or unfavorable conditions. If
we consider chemotherapy as one unfavorable condition that
cancer cells encounter, we might hypothesize that cells
adapted to survive in hypoxia should be more prone to sur-
vive under the selective pressure of chemotherapy. An accur-
ate choice of the type of chemotherapeutic drugs, together
with the combination of HIF-1α inhibitors, may ameliorate
the response of hypoxic tumors to chemotherapy.
An altered UPR impacts on sensitivity to chemotherapy
Few evidences reported that ER stress induces chemo-
sensitivity, as in the case of ovarian cancer cells and cis-
platin [148], or gastric cancer and doxorubicin/
vincristine [149], but in both cases the higher chemosen-
sitivity seems independent from the resistance to ER
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stress. Since under ER stressing conditions cells are
depleted of ATP if they cannot recover it via autophagy,
they activate a UPR-dependent apoptosis. At the same
time, the low levels of ATP deprive Pgp and other ABC
transporters of the energetic substrate for pumping out
chemotherapeutic drugs. These mechanisms may explain
why Pgp-expressing ovarian cancer cells subjected to ER
stress are sensitizied to paclitaxel [150].
Most often, however, an increased resistance to ER
stress, as it occurs in cells adapted to survive in a hypoxic
environment, determines chemoresistance.
For instance, glucose deprivation activates GRP78 that
in turn increases mdr1 gene transcription via c/Jun [151]
and mounts a cytoprotective autophagic reaction in
response to bortezomib in MM [152] or to vemurafemib
in resistant BRAFV600E mutated melanoma cells [153].
On the contrary, betulinic acid-induced activation of
GRP78 increases PERK/CHOP axis, promoting the apop-
tosis induced by taxol [154]. In accordance, the down-
regulation of GRP78, coupled with the up-regulation of
IRE1α, is associated with resistance to cisplatin in NSCLC
cells [155]. Also GRP78 downstream effectors may induce
chemoresistance. In PDAC cells, PERK induces chemore-
sistance by phosphorylating eIF2α that attenuates protein
translation and prevents the accumulation of unfolded
proteins within ER lumen, thus alleviating the proteostatic
stress. At the same time PERK activates ATF4/CHOP axis
that - contrarily to most cell types where CHOP is a pro-
apoptotic factor [156] - exerts anti-apoptotic effects and
induces resistance to gemcitabine [157]. The resistance to
gemcitabine in PDAC stem cells has been also linked to
the down-regulation of IRE1α and the simultaneous activa-
tion of PERK, that in turn up-regulate the urokinase plas-
minogen activator (uPA). uPA prevents the mitochondria-
dependent apoptosis elicited by gemcitabine [158], thus
promoting chemoresistance by activating a cross talk be-
tween ER and mitochondria. Defective ATF6 and XBP-1
determine resistance to bortezomib in MM, coupled with
reduced ER lumen and reduced ability to mount a UPR-
triggered cell death in response to proteostatic stress [159].
Accordingly, the block of E1-ubiquitin-activating enzyme
and the consequent proteostatic stress increase the expres-
sion of IRE1α, PERK and ATF6 that cooperate in inducing
apoptosis and increasing sensitivity to proteasome inhibi-
tors, doxorubicin, melphalan and lenalidomide [160].
As it occurs for the chemoresistance associated with
HIF-1α, the presence of oncogenic drivers pushes the
activation of specific ER stress sensors that induce che-
moresistance. For instance, in chronic myeloid leukemia
cells the BCR/ABL oncogene determines the constitutive
phosphorylation of PERK and eIF2α that prevent the ER
stress-dependent apoptosis in response to imatinib, as
demonstrated by the re-sensitization to the drug when
PERK/eIF2α activity is prevented [161]. In colon cancer,
breast cancer and osteosarcoma, PERK determines re-
sistance to oxaliplatin and doxorubicin, via the activation
of erythroid-derived 2-like 2 (Nrf2), which up-regulates
anti-oxidant enzymes and MRP1 [99], two actors in the
chemoresistant phenotype.
In a strict parallelism with the linkage between
hypoxia and chemoresistance, also the linkage between
resistance to ER stress and resistance to chemotherapy is
reciprocal. On the one hand, cells selected to survive
under mild and chronic ER stress conditions acquire
drug resistance by up-regulating PERK, similarly to cells
selected in medium with increasing concentrations of
chemotherapeutic drugs that acquire a MDR phenotype
[95]. On the other hand, cells with a MDR phenotype
are also resistant to ER stress induced-cell death: both
ER stressors and chemotherapeutic drugs – such as
doxorubicin, oxaliplatin/cisplatin, 5-fluorouracil – increase
the CCAAT/enhancer-binding protein-β (C/EBP-β) LIP
isoform that prevents the CHOP/caspase 3-mediated apop-
tosis and at the same time up-regulates Pgp [162]. Another
linkage between ER stress adaptation/resistance and che-
moresistance is provided by the observation that chemore-
sistant tumors often exhibit a defective ERAD/ERQC,
making them constantly subjected to a chronic proteostatic
stress. The adaptation to this chronic stressing condition
constitutively activates ER-dependent pro-survival path-
ways that contribute to chemoresistance [163, 164]. How-
ever, perturbing the unstable balance between defective
ERAD/ERQC system and compensatory up-regulation of
pro-survival pathways may hit ER stress-resistant/che-
moresistant cells in their Achille’s heel. Indeed, inducing
ER stress with ER-targeting doxorubicin perturbing disul-
fide bonds of proteins [164] or Ag-nanoparticles inducing
ER stress [165] restore chemosensitivity. The mechanism is
double. First, the accumulation of misfolded proteins
induces their ubiquitination and the engulfment of prote-
asome/autophagosome system. Second, Pgp is folded
within ER and stabilized by disulfide bonds: the interfer-
ence with these processes promotes its degradation, with
consequent decreased efflux of chemotherapeutic drugs
and sensitization to Pgp substrates [164–166].
Overall, the different stimuli that specifically activate
one or more UPR arms, the different nature and timing
of ER stressing conditions, the different pattern of UPR
downstream transducers explain why the mechanisms
linking ER stress and chemoresistance are multiple and
sometimes contrasting in different tumors. This variable
scenario is further complicated in the core of solid tu-
mors, because hypoxia is a cause of both ER stress and
chemoresistance, and may trigger additional circuitries
increasing at the same time the resistance to ER stres-
sing conditions and to chemotherapeutic drugs. For
these reasons, hypoxic tumors should be considered
characterized by a “multi-resistant” phenotype.
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The crosstalk between hypoxia and UPR-dependent
circuitries induces chemoresistance
Being two hallmarks of resiliency in cancers, hypoxia
and altered UPR response can cooperate in inducing
chemoresistance. Multiple crosstalks exist between the
pro-survival pathways activated by HIF-1α and UPR
(Fig. 3), and they can be enhanced by additional pro-
oncogenic conditions, such as mutated TP53 [167].
Hypoxia increases the expression of GRP78 that in
turn promotes an adaptive UPR response to the hypoxic
environment: peculiar events in this adaptation are the
down-regulation of CHOP and Bax, and the up-
regulation of Bcl-2. The increased Bcl-2/Bax ratio results
in the inhibition of apoptosis; in this way, the hypoxic-
driven up-regulation of GRP78 triggers resistance to
cisplatin [168]. Accordingly, GRP78-silencing restores
chemosensitivity, rewiring the pattern of CHOP/Bax/
Bcl-2 expression, notwithstanding the persistence of an
hypoxic environment [168]. GRP78 [151], as well as
HIF-1α [96], are transcriptional inducers of mdr1.
Therefore, hypoxia inevitably leads to resistance towards
the multiple chemotherapeutic drugs transported by
Pgp. The accumulation of GRP78 and prolyl 4-
hydroxlase, beta polypeptide (P4HB) in the ER lumen of
hypoxic glioblastoma cells maintains low the activity of
IRE1α and PERK/CHOP. Hyperoxia not only restores
the relative levels of PERK/CHOP and IRE1α, by reducing
GRP78 and P4HB, but it also enhances the apoptosis
Fig. 3 Hypoxia and UPR cooperate in inducing chemoresistance. In hypoxic cells, the ER stress sensors are activated and cooperate in inducing
chemoresistance. glucose-regulated protein 78 (GRP78) increases the anti-apoptotic Bcl-2/Bax ratio and transcriptionally induces ABC transporter
B1/multidrug resistance 1 (ABCB1/MDR1) gene by activating Janus kinase (JNK). Protein kinase R-like endoplasmic reticulum kinase/eukariotic
initiating factor 2α/activating transcription factor-4 (PERK/eIF2α/ATF-4) axis stabilizes the anti-apoptotic factor forkhead box O-1 (FOXO-1) and
activates the transcription factor erythroid-derived 2-like 2 (Nrf2), which in turn up-regulates ABC transporter C1/multidrug resistance related
protein 1 (ABCC1/MRP1), antioxidant enzymes and matrix metalloprotease 9 (MMP9). Together with PERK-dependent signalling, also inositol-
requiring enzyme-1α/X-box-binding protein 1 (IRE1α/XBP-1) and activating transcription factor-6 (ATF6)-dependent axes support hypoxia-
inducible factor-1α (HIF-1α) transcriptional program, contributing to the chemoresistance typical of hypoxic tumors
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induced by temozolomide [169]. Although temozolomide
mainly induces cell death by alkylating DNA, in an ER-
independent way, the sensitization to the drug cytotoxicity
is likely due to the induction of “two apoptotic hits”, the
first one at the DNA level, the second one at the ER level,
as suggested by the synergism achieved by hyperoxia and
temozolomide.
PERK/eIF2α/ATF4 axis is typically induced by hypoxia
[56] and contributes to the hypoxia-induced chemoresis-
tance with multiple mechanisms. First, PERK increases
the phosphorylation and activity of the anti-apoptotic
forkhead box O-1 (FOXO-1), together with pro-
autophagic factors [170]. The inhibition of apoptosis and
the increased autophagy concurrently protect cells from
chemotherapeutic drugs. Again, UPR-dependent and
hypoxia-dependent axes synergize, because HIF-1α in-
duces FOXO-1 transcription [171], promotes protective
autophagy [172] and activates PERK/eIF2α/ATF4 axis
[56]. By cooperating with HIF-1α in up-regulating
MMP9 [173], PERK and HIF-1α also promote migration,
helping cancer cells to leave unfavorable environments
and escape from cytotoxic agents. As mentioned above,
Nrf2 is also activated by PERK and confers chemoresis-
tance by up-regulating MRP1 [99] and anti-oxidant en-
zymes [170]. Of note, hypoxia-associated ROS up-regulate
both HIF-1α and Nrf2: the sum of their transcriptional
programs unequivocally worsens chemoresistance [174].
IRE1α/XBP-1 [79] and ATF6 [175] are activated in
hypoxic cells as well, although the role of such increase
in chemoresistance is not univocal. While the increase
of ATF6 and the decrease of IRE1α has been linked to
resistance to cisplatin in NSCLC [155], in MM the low
activity of both ATF6 and IRE-1α induces resistance to
bortezomib [159]. By contrast, XBP-1 up-regulation
determines a more aggressive phenotype in TNBC. In
this tumor, XBP-1 gene signature is strongly associated
with HIF-1α gene signature, and they correlate with a
lower relapse-free survival [84]. Since chemotherapy is
the first treatment option for TNBC, the high HIF-1α/
high XBP-1 phenotype could be indicative of poor re-
sponse to chemotherapeutic drugs and consequent lower
survival.
In addition, hypoxic niches are enriched of cancer
stem cells (CSCs) that are usually chemoresistant [176],
because they have higher expression of ABC transporters
[177, 178] and HIF-1α-mediated up-regulation of
MMP9, C-X-C chemokine receptor type 4 (CXCR4),
osteopontin, IL-8 and VEGF [179] that promote invasion
and chemoresistance. In addition, CSCs may show a dif-
ferential UPR response than differentiated cells [180].
For instance, cervical CSCs show high resistance to the
ER stress cell death induced by tunicamycin, because
they down-regulate pro-apoptotic pathways dependent
from IRE1α and activate pro-survival pathways
dependent from PERK. This shift also induces cisplatin
resistance that can be reversed by specific inhibitors of
IRE1α and PERK [180]. Colon CSCs have down-
regulated specific mediators of ER stress-dependent cell
death (such as CHOP) and are more resistant to chemo-
therapy with oxaliplatin, 5-fluorouracil and irinotecan.
Inducing ER stress with subtilase cytotoxin A, that
cleaves and activates GRP78, promotes chemosensitiza-
tion and loss of stemness phenotype [181]. Paradoxically,
chemotherapeutic drugs that induce a pro-apoptotic
UPR in differentiated cells, such as gemcitabine, activate
pro-survival and pro-invasive pathways dependent on
ATF6 in PDAC CSCs [158]. These findings suggest that
the acquisition of stemness properties, driven by the
growth in hypoxic environment, induces an altered UPR
that mediates chemoresistance.
The experimental evidences reported above clearly
indicate that the mechanisms linking UPR, hypoxia and
chemoresistance are multiple and often tumor-specific.
Being the results of an adaptive program to unfavorable
conditions, these mechanisms must be considered in a
dynamic perspective. Depending on the degree of hypoxia,
timing and exposure to chemotherapeutic drugs, the same
molecular axis can be turned-on or turned-off, activating
opposite and compensatory pathways that lead to cell
death or survival.
Conclusions and future perspectives
In solid tumors the hypoxic microenvironment deter-
mines a continuous ER stress. Like in the aphorism
“What does not kill me, makes me stronger”, the com-
bined pressure of two unfavourable conditions elimi-
nates the most sensitive cells, but it trains the most
resistant cells to survive and mount a network of adap-
tive responses to environmental stresses. This ability is
plastic and determines the progressive acquisition of
multiple resistances, e.g. resistance to oxidative stress, to
nutrient shortage, to chemotherapy. As a result of this
selective pressure, the most chemoresistant and aggres-
sive clones emerge during tumor progression. Since hyp-
oxia induces pro-survival UPR-dependent pathways and
chemoresistance, and an altered UPR mediates chemore-
sistance both in normoxia and hypoxia, disrupting these
vicious circles may help in finding new chemosensitizing
strategies or drug combinations inducing synthetic le-
thality (Fig. 4).
Several UPR activators (e.g. GRP78 activator perilly alco-
hol, ATF6 activator Δ9-tetrahydrocannabinol) or inhibitors
(e.g. GRP78 blocker epigallochetchin gallate, ATF6 blocker
ceapins, IRE1-α inhibitors salicylaldehyde-derivatives, PERK
inhibitors GSK2606414 and GSK2656157) have been
employed as inducers of apoptosis in cancer preclinical
models [182–184], but only few of them have reached clin-
ical trials (https://clinicaltrials.gov/ct2/results?term=drug+
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targeting+UPR). The multiple crosstalks, as well as the
involvement of UPR in several physiologic processes in
non-transformed tissues, make it difficult to have safe and
effective therapeutic strategies at the present. For instance,
GSK2656157 is a direct inhibitor of PERK: since PERK is a
key actor in the hypoxia-mediated chemoresistance, it has
been administered in PDAC xenografts that are notoriously
refractory to the majority of treatments [185]. Although
GSK2656157 successfully reduced tumor growth, decreased
vessel density and altered aminoacid metabolism, it also
damaged pancreatic β-cells [185]. Therefore, the risk of
insulin resistance or diabetes disencouraged from using
GSK2656157 in patients. To limit the damages on normal
tissues, hypoxia-activated PERK inhibitor prodrugs have
been produced, by using a 2-nitroimidazole moiety that is
enzymatically reduced in hypoxic conditions into the active
drug. The first tests in colon cancer cells were promising,
although these prodrugs effectively inhibited PERK only in
the micromolar range [186]. At this concentration, the risk
of off-target effects is high, raising questions on the feasibil-
ity of this approach in patients.
Also, HIF-1α targeting is complicated because of the
multiple pathways that control HIF-1α expression and of
the multiple transcriptional programs that are controlled
by HIF-1α. Inhibitors of HIF-1α translation (EZN-29-68,
PX-478, Vorinostat, digoxin), stability (PX-478, Vorinostat,
YC-1) and transcriptional activity (YC-1, acriflavine), or in-
hibitors of HIF-1α upstream inducers, as PI3K/Akt/mTOR
axis, are the most used drugs at the present [187, 188].
Some of these compounds have shown good chemosensi-
tizing effects. In several preclinical models of solid and
hematologic tumors, direct inhibitors of HIF-1α, such as
YC-1 [103] and BAY87-2243 [189], or indirect down-
regulators of HIF-1α signalling, as the anti-androgen
dutasteride [190], the alkaloid emetine [191], the lncRNA
HITT [192] – one of the multiple ncRNA that regulate
HIF-1α [193] –, have induced chemosensitization, by redu-
cing HIF-1α transcriptional activity. The disadvantage of
these inhibitors is their aspecificity. In order to overcome
this limitation, the first liposomal formulations containing
acriflavine co-encapsulated with doxorubicin have been
produced, and demostrated a superior tumor targeting and
anti-tumor efficacy than doxorubicin alone [173]. Cur-
rently, more than 100 trials are testing HIF-1α inhibitors as
anti-cancer agents (https://clinicaltrials.gov/ct2/results/
details?cond=Cancer&term=HIF), despite the results were
below the expectations. A partial explanation of this failure
is that HIF-1α is a hallmark of aggressive and resistant can-
cers. Indeed, HIF-1α presence is a synonimous of cells
characterized by multiple and redundant resistance path-
ways: the inhibition of HIF-1α can only partially turn-off
their pro-survival attitude.
Pharmacological interventions on multiple pathways
can achieve better results. In this perspective, the simul-
taneous targeting of UPR and HIF-1α can be considered a
valid approach. For instance, geldanamycin, a HSP90 in-
hibitor, induces at the same time ER stress and HIF-1α
ubiquitination, down-regulating its angiogenetic transcrip-
tional program [194]. Bortezomib and nelfinavir, two
drugs able to elicit ER stress by inducing a proteostatic
stress [159, 195], also down-regulate HIF-1α activity [196,
197]. These few examples highlight that the dual targeting
of UPR and HIF-1α with FDA-approved drugs is feasible.
This drug-repurposing strategy can be exploited as a new
chemosensitizing approach, although problematic toxic-
ities in patients cannot be excluded also in this case.
Fig. 4 HIF-1α- and UPR-targeting drugs as new chemosensitizing agents. Pharmacological inhbitors (red crosses) or activators (red arrows) of
hypoxia-inducible factor-1α (HIF-1α) or unfolded protein response (UPR) actors - glucose-regulated protein 78 (GRP78), protein kinase R-like
endoplasmic reticulum kinase/eukariotic initiating factor 2α/activating transcription factor-4 (PERK/eIF2α/ATF-4), inositol-requiring enzyme-1α/X-
box-binding protein 1 (IRE1α/XBP-1) and activating transcription factor-6 (ATF6) – can be repurposed as chemosensitizing agents in hypoxic
tumors. Δ9-THC: Δ9-tetrahydrocannabinol
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Although not translable to patients in the present, the
pharmacological and mechanistic studies on the cross-talk
between hypoxia, UPR and chemoresistance, are useful to
put together the pieces of the puzzle linking these three
players. Increasing our understanding on these circuitries
will steer the pharmacological research towards more pre-
cise and effetive approaches to counteract hypoxic and
chemoresistant tumors in the next future.
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